Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Pharming   /   Pharming het aandeel van 2017

Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

Laatste koers (eur) Verschil Volume
0,893   +0,020   (+2,23%) Dagrange 0,884 - 0,901 3.728.995   Gem. (3M) 6,5M

Pharming het aandeel van 2017

Volgen
50.750 Posts
Pagina: «« 1 ... 1934 1935 1936 1937 1938 ... 2538 »» | Laatste | Omlaag ↓
  1. jandekkers 10 oktober 2017 08:07
    Pharmacy Management Drug Policy
    Hereditary Angioedema (HAE)
    Proprietary of the Insurance Plan Page 4 of 7
    E. Firazyr specific criteria
    1. Must have a diagnosis of hereditary angioedema (progress notes required)
    2. Must be used for acute episodic attacks--Safety and efficacy as prophylactic therapy
    has not been established and therefore will not be covered
    3. Firazyr has potential to attenuate antihypertensive effects of ACE inhibitors and should
    not be administered to patients taking ACE inhibitors since there are no clinical trials in
    this population
    4. Standard dosing is 30mg subcutaneously injected into abdominal area; if response is
    inadequate or symptoms recur additional injections of 30mg may be administered at
    intervals of at least 6 hours with no more than 3 doses per 24 hour period
    5. Quantity limit of #3 (3ml each) pre-filled syringes – 9ml/30 days.
    6. Authorization will be for 6 months at a time
    a. Recertification will require documentation of decrease in severity or
    duration of attacks. Documentation including frequency of administration will also
    be required at time of recertification to monitor for appropriate use.
    7. Safety and Efficacy in anyone under 18 years old is not established and therefore will
    not be covered.
    8. Firazyr can be self-administered upon recognition of an HAE attack after training under
    the guidance of a healthcare professional and therefore will be covered under the
    pharmacy benefit.
    F. Ruconest specific criteria
    1. Must have a diagnosis of acute attacks associated with hereditary angioedema
    (progress notes required)
    2. Ruconest will not be covered for laryngeal attacks as efficacy has not been established
    in patients with laryngeal HAE attacks
    3. Safety and efficacy in children under the age of 13 has not been established and
    therefore will not be covered
    4. Ruconest will be reviewed under the medical benefit when administered by a health
    care professional. If the member transitions to self-administration, then Ruconest can
    be authorized under the pharmacy benefit.
    5. Must have documentation of therapeutic failure or severe adverse reaction to Berinert or
    Firazyr
    6. Dose is 50 IU per kg by IV injection
    a. Maximum dose is 4200 IU with no more than 2 doses within a 24 hour time
    period
    b. Quantity limit of 100 ml per 30 days
    c. Authorization on the medical benefit will be for 1 month initially then every 6
    months
    d. Authorization on the pharmacy benefit will be for 6 months at a time
    e. Recertification will require documentation of decrease in severity or duration of
    attacks. Documentation including frequency of administration will also be
    required at time of recertification to monitor for appropriate use
    7. Based on national shortages of other medications that are FDA approved for HAE
    prophylaxis and emerging clinical data, requests for Ruconest for hereditary
    angioedema prophylaxis will be allowed with the following dosing:
    Pharmacy Management Drug Policy
    Hereditary Angioedema (HAE)
    Proprietary of the Insurance Plan Page 5 of 7
    50 IU per kg for patients less than 84 kg or 4200 IU for patients greater than or equal to
    84 kg twice weekly
    a. Quantity limit of 16 vials per 28 days
    b. Approvals will be short term (2 months) until supply of other medications that are
    FDA approved for HAE prophylaxis is adequate.
    G. Haegarda specific criteria
    1. Must have a diagnosis of hereditary angioedema (progress notes required)
    2. Must be used as a prophylaxis – not for acute treatment
    3. For long term prophylaxis, the patient must meet the following:
    a. History of at least two severe HAE attacks (i.e. airway swelling, debilitating
    cutaneous or gastrointestinal episodes) per month that resulted in loss of
    work/school productivity or ER/unscheduled doctor visits OR disability for > 5 days
    per month due to HAE AND
    b. Patient has a documented contraindication, severe intolerance, or therapeutic
    failure to 17 alpha-alkylated androgens (e.g. danazol) for HAE prophylaxis AND
    c. Treatment with acute therapy (i.e. Kalbitor, Firazyr, Berinert or Ruconest) did not
    result in meaningful outcomes such as decreased severity of attacks, avoidance
    of hospitalization, etc
    4. Haegarda will be allowed for short-term prophylaxis if being requested prior to medical,
    surgical or dental procedure. Approval will be for one month only.
    5. Haegarda can be self-administered after training under the guidance of a healthcare
    professional and therefore will be covered under the pharmacy benefit.
    6. Standard dosage is 60 International Units (IU) per kg body weight by subcutaneous
    injection twice weekly.
    a. Quantity limit of 16 vials per 28 days (defined as the combined total amount of
    2000 unit vials AND 3000 unit vials)
    b. Requests will require documentation of patient’s weight to verify requested
    dosing is in accordance to the FDA approved dosing.
    c. Requests for dosing every three days will require documentation of a previous
    trial of twice weekly dosing that did not lead to a decrease in the severity,
    duration and/or frequency of attacks.
    7. Authorization will be for 6 months at a time.
    a. Recertification will require documentation of decrease in the severity, duration,
    and/or frequency of attacks. Documentation including frequency of administration
    will also be required at time of recertification to monitor for appropriate use.
    8. Safety and efficacy in children under the age of 13 has not been established and
    therefore will not be covered
    POLICY GUIDELINES:
    1. Prior-authorization is contract dependent.
    2. A normal C4 particularly during an edema attack should make one question the diagnosis of HAE
    3. Some medications may trigger or worsen angioedema events in patients with HAE and should be
    avoided including estrogen contraceptives, hormone replacement therapy, and ACE-Inhibitors.
  4. [verwijderd] 10 oktober 2017 08:14
    quote:

    C200 schreef op 10 oktober 2017 08:08:

    [...]

    Dank je Jan, maar dat hoeft niet.

    Ik bedoel, als er geen officieel persbericht van komt zal het imo weinig met de koers doen. Dus als Sijmen slim is, brengt hij het even naar buiten.
    Pharming dacht ik gelezen te hebben mag in deze fase geen promotie maken voor profylactisch gebruik van Ruconest
  16. mickjagger2 10 oktober 2017 08:48
    F. Ruconest specific criteria
    1. Must have a diagnosis of acute attacks associated with hereditary angioedema
    (progress notes required)
    2. Ruconest will not be covered for laryngeal attacks as efficacy has not been established
    in patients with laryngeal HAE attacks
    3. Safety and efficacy in children under the age of 13 has not been established and
    therefore will not be covered
    4. Ruconest will be reviewed under the medical benefit when administered by a health
    care professional. If the member transitions to self-administration, then Ruconest can
    be authorized under the pharmacy benefit.
    5. Must have documentation of therapeutic failure or severe adverse reaction to Berinert or
    Firazyr
    6. Dose is 50 IU per kg by IV injection
    a. Maximum dose is 4200 IU with no more than 2 doses within a 24 hour time
    period
    b. Quantity limit of 100 ml per 30 days
    c. Authorization on the medical benefit will be for 1 month initially then every 6
    months
    d. Authorization on the pharmacy benefit will be for 6 months at a time
    e. Recertification will require documentation of decrease in severity or duration of
    attacks. Documentation including frequency of administration will also be
    required at time of recertification to monitor for appropriate use
    7. Based on national shortages of other medications that are FDA approved for HAE
    prophylaxis and emerging clinical data, requests for Ruconest for hereditary
    angioedema prophylaxis will be allowed with the following dosing:
    Pharmacy Management Drug Policy
    Hereditary Angioedema (HAE)
    Proprietary of the Insurance Plan Page 5 of 7
    50 IU per kg for patients less than 84 kg or 4200 IU for patients greater than or equal to
    84 kg twice weekly
    a. Quantity limit of 16 vials per 28 days
    b. Approvals will be short term (2 months) until supply of other medications that are
    FDA approved for HAE prophylaxis is adequate

    Thanks jandekkers AB
50.750 Posts
Pagina: «« 1 ... 1934 1935 1936 1937 1938 ... 2538 »» | Laatste |Omhoog ↑

Direct naar Forum

Premium

Update: Gedurfde overnamezet van Pharming

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Pharming Nieuws

  1. CEO: Pharming koopt met KL1333 van Abliva goede kans op blockbuster (video)
  2. RBC verhoogt koersdoel Pharming fors
  3. Afwachtend begin van Super Central Bank-week en we hebben een beursganger
  4. CEO De Vries: Pharming dicht bij overname van nieuwe blockbuster
  5. Pharming brengt bod op Abliva AB uit
  6. Moeizame week voor financials
  7. Weekoverzicht: vastgoed uit de gratie, winst voor automotive en chipaandelen
  8. Fundlogic verkleint belang in Pharming
  9. Fundlogic meldt belang in Pharming
  10. Jefferies: positieve studiedata Pharming vergroten doelgroep Joenja